CN116004520A - 带双安全开关的诱导多功能干细胞及其制备方法 - Google Patents
带双安全开关的诱导多功能干细胞及其制备方法 Download PDFInfo
- Publication number
- CN116004520A CN116004520A CN202310019818.7A CN202310019818A CN116004520A CN 116004520 A CN116004520 A CN 116004520A CN 202310019818 A CN202310019818 A CN 202310019818A CN 116004520 A CN116004520 A CN 116004520A
- Authority
- CN
- China
- Prior art keywords
- gene
- seq
- aavs1
- double safety
- ips cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 238000002659 cell therapy Methods 0.000 claims abstract description 10
- 101150018757 CD19 gene Proteins 0.000 claims abstract description 9
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 102000004039 Caspase-9 Human genes 0.000 claims abstract description 7
- 108090000566 Caspase-9 Proteins 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 230000033667 organ regeneration Effects 0.000 claims description 5
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 6
- 206010043276 Teratoma Diseases 0.000 abstract description 5
- 238000010362 genome editing Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract description 2
- 108091033409 CRISPR Proteins 0.000 description 10
- 239000013598 vector Substances 0.000 description 7
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 101150037203 Sox2 gene Proteins 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000599458 Homo sapiens Protein phosphatase inhibitor 2 family member C Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100037977 Protein phosphatase inhibitor 2 family member C Human genes 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310019818.7A CN116004520A (zh) | 2023-01-06 | 2023-01-06 | 带双安全开关的诱导多功能干细胞及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310019818.7A CN116004520A (zh) | 2023-01-06 | 2023-01-06 | 带双安全开关的诱导多功能干细胞及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116004520A true CN116004520A (zh) | 2023-04-25 |
Family
ID=86024535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310019818.7A Pending CN116004520A (zh) | 2023-01-06 | 2023-01-06 | 带双安全开关的诱导多功能干细胞及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116004520A (zh) |
-
2023
- 2023-01-06 CN CN202310019818.7A patent/CN116004520A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hendriks et al. | CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids | |
US10280402B2 (en) | Immune-compatible cells created by nuclease-mediated editing of genes encoding HLA | |
JP2021106611A (ja) | ヌクレアーゼ介在性遺伝子発現調節 | |
EP3487992A2 (en) | Methods and compositions for modifying genomic dna | |
Diecke et al. | Recent technological updates and clinical applications of induced pluripotent stem cells | |
CN109750035B (zh) | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA | |
US20090191171A1 (en) | Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination | |
CN106086031B (zh) | 猪肌抑素基因编辑位点及其应用 | |
WO2020257325A1 (en) | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | |
CN111575319B (zh) | 一种高效的crispr rnp和供体dna共位介导的基因插入或替换方法及其应用 | |
CN108778299A (zh) | 生成无载体诱导多能干细胞的载体和方法 | |
CN113302292A (zh) | 遗传修饰细胞的减少和最少的操作制造 | |
WO2009092042A1 (en) | Reprogramming of differentiated progenitor or somatic cells using homologous recombination | |
CN106754949B (zh) | 猪肌抑素基因编辑位点864-883及其应用 | |
WO2021034984A2 (en) | Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators | |
Rodríguez-Polo et al. | Non-human primate pluripotent stem cells for the preclinical testing of regenerative therapies | |
Patmanathan et al. | CRISPR/Cas9 in stem cell research: current application and future perspective | |
US20240060047A1 (en) | Cells with sustained transgene expression | |
US20220364072A1 (en) | Fusion protein that improves gene editing efficiency and application thereof | |
US20210379105A1 (en) | Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked agammaglobulinemia (xla) | |
CN113748126A (zh) | 鉴定免疫调节基因的方法 | |
CN113316637A (zh) | 依靠人工反式激活物的选择 | |
CN116004520A (zh) | 带双安全开关的诱导多功能干细胞及其制备方法 | |
Argani | Genome engineering for stem cell transplantation | |
CN115141817B (zh) | 一种细胞中hbb基因修复的方法及产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240329 Address after: 250101 Export Processing Zone, Jinan High-tech Zone, Shandong Province, 1109 Gangxing Third Road Applicant after: Shandong Yinfeng Institute of Life Sciences Country or region after: China Applicant after: YINFENG BIOLOGICAL GROUP Co.,Ltd. Applicant after: HUNAN SHENGBAO BIOTECHNOLOGY CO.,LTD. Address before: 250101 Export Processing Zone, Jinan High-tech Zone, Shandong Province, 1109 Gangxing Third Road Applicant before: Shandong Yinfeng Institute of Life Sciences Country or region before: China Applicant before: YINFENG BIOLOGICAL GROUP Co.,Ltd. |